Сравнительный анализ результатов монотерапии бикалютамидом и кастрации у больных неметастатическим местно-распространенным раком предстательной железы при сроке наблюдения 6,3 года
https://doi.org/10.17650/1726-9776-2008-4-1-48-54
Аннотация
Статья впервые опубликована в J. Urol. Vol. 164, 1579—1582, November 2000.
Об авторах
P. IversenРоссия
C. J. Tyrrel
Россия
A. V. Kaisary
Россия
J. B. Anderson
Россия
H. van Poppel
Россия
T. L.J. Tammela
Россия
M. Chamberlain
Россия
K. Carrol
Россия
I. Melezinek
Россия
Список литературы
1. Landis S.H., Murray T., Bolden S. et al. Cancer statistics, 1999. CA Cancer J Clin 1999;49: 8.
2. Kirby R. Treatment options for early prostate cancer. Urology 1998;52:948.
3. Cassileth B.R., Soloway M.S., Vogelzang N.J. et al. Patients' choice of treatment in stage D prostate cancer. Urology 1989; 33 (Suppl): 57.
4. Fossa S.D., Aass N., Opjordsmoen S. Assessment of quality of life in patients with prostate cancer. Semin Oncol 1994;21: 657.
5. Lucas M.D., Strijdom S.C., Berk M. et al. Quality of life, sexual functioning and sex role identity after surgical orchi-dectomy in patients with prostatic cancer. Scand J Urol Nephrol 1995;29: 497.
6. Daniell H.W., Dunn S.R., Ferguson D.W. et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163: 181.
7. van Basten J.P., van Driel M.F., Jonker-Pool G. et al. Sexual functioning in testosterone-supplemented patients treated for bilateral testicular cancer. Br J Urol 199779: 461.
8. Eastell R., Boyle I.T., Compston J. et al. Management of male osteoporosis: report of the UK Consensus Group. QJM 1998;91: 71.
9. Jackson J.A., Riggs M.W., Spiekerman A.M. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci 1992;304: 4.
10. Verhelst J., Denis L., van Vliet P. et al. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) 1994;41: 525.
11. Kolvenbag G.J., Nash A. Bicalutamide dosages used in the treatment of prostate cancer. Prostate 1999;39: 47.
12. Boccardo F., Rubagotti A., Barichello M. et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999;17: 2027.
13. Chatelain C., Rousseau V., Cosaert J. French multicentre trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a pre-liminary report. Eur Urol 1994; 26 (Suppl): 10.
14. Chatelain C., Fourcade R.O., Delchambre J. Bicalutamide (Casodex®) versus combined androgen blockade (CAB): open French multicentre study in patients with metastatic prostate cancer. Br J Urol 1997; 80 (Suppl): 283, abstract 1111.
15. Tyrrell C.J., Kaisary A.V., Iversen P. et al. A randomized comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33: 447.
16. Iversen P., Tyrrell C.J., Kaisary A.V. et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998;51: 389.
17. Cleary P.D., Morrissey G., Oster G. Health-related quality of life in patients with advanced prostate cancer: a multinational perspective. Qual Life Res 1995;4: 207.
18. Iversen P. Quality of life issues relating to endocrine treatment options. Eur Urol 1999; 36 (Suppl): 20,
19. Mazur D.J., Hickam D.H. Patient preferences: survival vs quality-of-life considerations. J Gen Intern Med 1993;8: 374.
20. Tyrrell C.J. Gynaecomastia: aetiology and treatment options. Prost Cancer Frost Dis 1999;2: 167.
Рецензия
Для цитирования:
Iversen P., Tyrrel C.J., Kaisary A.V., Anderson J.B., van Poppel H., Tammela T.L., Chamberlain M., Carrol K., Melezinek I. Сравнительный анализ результатов монотерапии бикалютамидом и кастрации у больных неметастатическим местно-распространенным раком предстательной железы при сроке наблюдения 6,3 года. Онкоурология. 2008;4(1):48-54. https://doi.org/10.17650/1726-9776-2008-4-1-48-54
For citation:
Iversen P., Tyrrel C.J., Kaisary A.V., Anderson J.B., van Poppel H., Tammela T.L., Chamberlain M., Carrol K., Melezinek I. Analysis of results of bicalutamide monotherapy versus castration in patients with non-metastatic locally advanced prostate cancer during 6.3-year follow-up. Cancer Urology. 2008;4(1):48-54. (In Russ.) https://doi.org/10.17650/1726-9776-2008-4-1-48-54
Просмотров: 182
Послать статью по эл. почте 
